Biological and Biosimilars Drug Market in Poland 2013

Publisher Name :
Date: 31-Aug-2013
No. of pages: 120

Examine the future of biologics in the Polish pharma market.

Report surveys biologic and biosimilar drugs, epidemiology and growth potential 2013- 2015.

In Poland, as in many parts of the world, a growing number of patients are being treated using biological or biosimilar drugs. The list of illnesses for which these drugs are prescribed includes psoriasis, Crohn’s disease, colitis, psoriatic and rheumatoid arthritis, ankylosing spondylitis and others. Consequently, the market has expanded recently to encompass new drugs and therapies designed to treat a growing variety of conditions and illnesses.

Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a new PMR report designed to evaluate current market conditions and investigate the possibilities for growth and expansion in the coming years. From market size to research and development efforts of leading companies, this publication offers expert analysis of this market.

This document analyses the epidemiology fueling the growth of biologics in Poland, revealing the number of patients receiving these drugs. It analyses the reasons behind expansion and the potential obstacles that exist or will appear by 2015.

The competitive atmosphere of this segment of Poland’s pharmaceuticals market is carefully evaluated using profiles of the major Polish manufacturing companies active in this market that include financial condition updates, plans for upcoming additions to their product lines and plans to engage in new research and development activities. Recent entries into the Polish biologics market are examined along with the likelihood of M&A and consolidation activity in the next two years.

The expiration of various patents for biologic drugs is a timely market topic, and this publication highlights the businesses ready to capitalise on new developments. It reviews the mechanics of the market, offering explanation of the registration and refund procedures that apply to biologics in Poland and covering recent and upcoming regulatory changes and their likely impact on businesses supplying this market.

Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a long-awaited business information tool that will aid companies involved in the manufacturing and distribution of these drugs within the Polish market and especially those which want to enter this young market. Related companies engaged in ingredient manufacturing and drug research will also find this report vital to new drug development, keeping up with legal requirements for business operation in this segment and preparing corporate reports and forecasts for internal use. Users of this publication come from pharmaceutical companies, consulting and research services providers and government agencies, financial institutions and chambers of commerce.

Biological and Biosimilars Drug Market in Poland 2013

Table Of Contents

I. Methodology 9

II. Executive summary 15

III. Market overview 19

IV. Results of the survey conducted among 35 companies operating on the market of biologicals and biosimilars in Poland 37

V. Biologicals in treatment of selected diseases in Poland 49

VI. Profiles of selected companies operating in the sector in Poland 97

VII. List of graphs 113

VIII. List of tables 117

IX. About PMR 119

  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Global Biosimilars Market 2014-2018
    Published: 14-Feb-2014        Price: US $3000 Onwards        Pages: 106
    TechNavio's analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. TechNavio's report, the Global Biosimilars Market 2014-2018, has been pre......
  • Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) – Global Forecast to 2018
    Published: 18-Nov-2013        Price: US $4650 Onwards        Pages: 320
    The global is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 and 2018. The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down ......
  • Therapy Class Overview : Rituximab Biosimilar
    Published: 7-Oct-2013        Price: US $2000 Onwards        
    Approval of Inflectra/Remsima,  the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year.  This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc......
  • The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition
    Published: 22-Sep-2013        Price: US $2995 Onwards        Pages: 195
    This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greate......
  • Biosimilar Opportunities in an Evolving Market
    Published: 1-Aug-2013        Price: US $1495 Onwards        Pages: 113
    Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency's Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson's infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two successful applicants, Celltrion and Hospira, this development passes a significant milestone for the whole biosimilar sector as the products are the first ......
  • Biologics and Biosimilars World Markets
    Published: 1-Aug-2013        Price: US $3400 Onwards        Pages: 403
    Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics additionally comprise recombinant insulin, growth hormone and monoclonal antibodies for treating conditions such as cancer and autoimmunity. Also known as follow-on biologics or subsequent entry biologics (SEBs), biosimilars are to biologics what generics are to branded drugs; they lower healthcare expenditures. This TriMark Publications report describes the emergence of biologics and biosimil......
  • PharmaSphere: Global Biosimilars Strategy – Regulatory Landscape, Key Drivers, Markets and Trends in 2013
    Published: 27-May-2013        Price: US $2995 Onwards        Pages: 152
    Summary GlobalData’s "PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013", provides strategic analysis of the global biosimilars industry. It discusses key market trends, regulatory requirements in various markets, recent deals activity and trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets s......
  • Therapeutic Class Report Overview – Rituxan Biosimilar
    Published: 4-Feb-2013        Price: US $2000 Onwards        Pages: 45
    The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years.  Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection.  Out of them, Roche’s/Biogen Idec’s Rituxan/MabThera (rituximab), Merck and JNJ’s Remicade (infliximab), and Amgen and Pfizer’s Enbrel (etanercept) had WW sales of ~$23b in 2011 and have  patents expiring in EU and ROW in 2013/14.  Biosimilar version......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs